Fresolimumab Biosimilar – Anti-TGFB, TGF beta mAb – Research Grade

Description of Fresolimumab Biosimilar - Anti-TGFB, TGF beta mAb - Research Grade

Introduction

Fresolimumab Biosimilar, also known as Anti-TGFB or TGF beta mAb, is a monoclonal antibody that targets the transforming growth factor beta (TGF-beta) protein. It is a research grade antibody with potential therapeutic applications in various diseases. In this article, we will discuss the structure, activity, and potential applications of Fresolimumab Biosimilar.

Structure of Fresolimumab Biosimilar

Fresolimumab Biosimilar is a fully human monoclonal antibody that is produced using recombinant DNA technology. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab region is responsible for binding to the target protein, while the Fc region mediates effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Activity of Fresolimumab Biosimilar

Fresolimumab Biosimilar specifically targets the active form of TGF-beta, which is a multifunctional cytokine involved in various cellular processes such as cell growth, differentiation, and immune response. TGF-beta plays a crucial role in tissue repair and regeneration, but its dysregulation has been linked to the development of many diseases, including cancer, fibrosis, and autoimmune disorders. Fresolimumab Biosimilar binds to TGF-beta with high affinity and blocks its interaction with its receptors, thereby inhibiting its downstream signaling pathways.

Applications of Fresolimumab Biosimilar

1.

Cancer Treatment

TGF-beta has been shown to promote tumor growth, invasion, and metastasis in various types of cancer. By blocking TGF-beta signaling, Fresolimumab Biosimilar has the potential to inhibit tumor growth and metastasis. In preclinical studies, it has shown promising results in suppressing the growth of breast, lung, and pancreatic tumors. Clinical trials are currently underway to evaluate the efficacy of Fresolimumab Biosimilar in combination with other cancer therapies.

2. Fibrotic Diseases Fibrosis is a common pathological process characterized by excessive deposition of extracellular matrix, leading to tissue scarring and organ dysfunction. TGF-beta is a key mediator of fibrosis, and its inhibition has been shown to prevent and reverse fibrosis in various organs, including the liver, lungs, and kidneys. Fresolimumab Biosimilar has shown efficacy in preclinical models of fibrotic diseases, and clinical trials are ongoing to evaluate its potential as a treatment for conditions such as idiopathic pulmonary fibrosis and systemic sclerosis.

3.

Autoimmune Disorders

TGF-beta is known to play a role in regulating the immune response, and its dysregulation has been linked to the development of autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. By blocking TGF-beta signaling, Fresolimumab Biosimilar has the potential to modulate the immune response and reduce inflammation in these conditions. Clinical trials are currently underway to evaluate its efficacy in treating autoimmune disorders.

4. Wound Healing TGF-beta plays a crucial role in wound healing by promoting the formation of new blood vessels and stimulating the production of extracellular matrix. However, excessive TGF-beta signaling can lead to excessive scarring and impaired wound healing. Fresolimumab Biosimilar has shown promise in promoting wound healing in preclinical studies and is currently being evaluated in clinical trials for the treatment of diabetic foot ulcers.

Conclusion

Fresolimumab Biosimilar, a research grade antibody that targets TGF-beta, has shown promising results in preclinical studies and is currently being evaluated in clinical trials for various diseases. Its unique mechanism of action makes it a potential therapeutic option for cancer, fibrotic diseases, autoimmune disorders, and wound healing. Further research and clinical trials will provide more insights into the efficacy and safety of this antibody and its potential as a treatment for these conditions.

Fresolimumab Biosimilar - Anti-TGFB, TGF beta mAb binds to Human TGFB1/TGF-beta-1 in indirect ELISA Assay

Immobilized TGFB1 recombinant protein (cat. No. PX-P5187) at 0.5µg/mL (100µL/well) can bind Fresolimumab Biosimilar - Anti-TGFB, TGF beta mAb (cat. No. PX-TA1128) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 217.5M.